Cabozantinib Intermediate,Bicalutamide Intermediate,Empagliflozin Intermediate,Enzalutamide Intermediate Manufacturer and Supplier in China

About Us

Shandong Haohong Biotechnology Co., Ltd. is located in Provincial Chemical Industrial Park of Liaocheng city, Shandong province, which is a beautiful water city. The total production area is around 130 thousand square meters, with 40 employees and 12 R&D technicians. Our company focuses on the development and production of pharmaceutical products, with 13 sets of 50L to 5000L reactors, and the annual manufacturing capacity can up to 500 tons. We had advanced sewage treatment system, with the daily processing capacity of 1000 tons. The new R&D laboratory is located on the 4th floor of the accelerator middle section of Qilu Science and Technology Town, Qilu High-tech Development Zone, Shandong Province, and is located in a large modern ecological science and technology park in Qihe Science and Technology City of Zhongguancun Haidian Park. Our company mainly focuses on the development of anti-cancer, anti-diabets series of API and its advanced intermediates. The main products include Bicalutamide, enzalutamide, apalutamide, macitentan, cabozantinib, ceritinib, empagliflozin, tofacitinib citrate, and alectinib,etc. In line with the concept of "truth-seeking, innovation and integrity", we had exported our products to the United States, European countries, Japan, India, Bangladesh and other overseas markets. At present, Our company has dozens of advanced intermediates, all of which are commercialized, and at the same time, we can provide customers with efficient customized synthesis services from grams to 100 kilograms. We will continue to provide high quality products with most competitive prices and good service to customers all over the world. We sincerely hope to establish stable and strategic business relationships with customers from home and abroad. Welcome to visit our website: www.haohongtech.com www.haohongpharma.com

View More Visit My Factory

News Center

ERLEADA® (Apalutamide) shows quickly, deeply and lastingly reduce the prostate specific antigen (PSA), with high compliance!

December 03, 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also supports the use of PSA as a predictive biomarker in the treatment of patients with advanced prostate cancer. These findings were presented during two podium sessions at the virtual American Urological Association Annual Meeting (AUA 2021), September 10-13. The post-hoc analysis (Abstract #PD34-11) of the Phase 3 TITAN and SPARTAN studies examined PSA kinetics in 2,259 patients with either mCSPC (TITAN) or nmCRPC (SPARTAN). Results showed that patients with advanced prostate cancer, whether mCSPC or nmCRPC, treated with ERLEADA® plus androgen deprivation therapy (ADT) had rapid, deep and durable PSA declines as early as three months and continuing beyond a year after initiating ERLEADA® therapy.1 In mCSPC (TITAN), the percentage of patients with a PSA decline of ≥50 percent or ≥90 percent or with an undetectable PSA (<0.2ng/mL) was approximately three times higher for patients treated with ERLEADA® plus ADT, compared to patients treated with ADT alone.1 In nmCRPC (SPARTAN), no PSA decline was observed in patients treated with ADT alone, as may be expected, but the addition of ERLEADA® showed robust PSA decline, including undetectable levels in a significant proportion of patients, similar to TITAN.
KRAS mutant lung cancer new drug: targeted drug Lumakras

November 30, 2021

LUMAKRAS (sotorasib, sotorasib, AMG510) launched by Amgen is a RAS GTPase inhibitor for the treatment of adult non-small cell lung cancer (NSCLC) patients, including spread to other parts of the body or unable to Adult patients with non-small cell lung cancer (NSCLC) that have been surgically removed, as well as patients whose tumors have abnormal KRAS G12C genes and have received at least one cancer treatment. According to the post-analysis data of the ongoing Phase 1/2 CodeBreaK 100 trial (NCT03600883) announced during the World Lung Cancer Congress in 2021, KRAS G12C mutant non-small cell lung cancer (NSCLC) and patients with stable brain metastases (previously received radiotherapy) Or surgery), after treatment with Lumakras, strong anti-cancer activity was observed (complete intracranial remission and sustained intracranial stability). On May 28, 2021, AMGEN announced that the U.S. FDA has accelerated the approval of the KRAS G12C inhibitor Lumakras for the treatment of locally advanced or metastatic non-small cell lung cancer with KRAS G12C mutation that has received at least one systemic treatment in the past ( NSCLC) patients. After Lumakras was approved by the FDA, on September 10, 2021, officials from the British drug and health care product regulatory agency approved the drug to enter the ORBIS project, which allows different regulatory agencies to cooperate in cancer drug review. On September 16, 2021, Amgen announced the results of the first joint study of the Phase 1b/2 CodeBreaK 101 study, which is the most comprehensive global

AbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ® (Upadacitinib) Among Patients with Rheumatoid Arthritis

November 19, 2021

AbbVie today announced new results from a post-hoc analysis of the Phase 3 SELECT-BEYOND clinical trial evaluating RINVOQ® (upadacitinib; 15 mg, once daily) in patients with moderate to severe rheumatoid arthritis (RA) on stable background of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) with prior inadequate response or intolerance to at least one biologic DMARD. Results showed that 34% of patients receiving RINVOQ and background csDMARDs achieved Clinical Disease Activity Index (CDAI) remission (CDAI ≤2.8) at first occurrence of response before week 60, while 79% achieved CDAI low disease activity (LDA) (CDAI ≤10).1 Maintenance of response, defined as not losing response at two consecutive study visits, was seen for CDAI remission and CDAI LDA in 39% and 61% of patients, respectively, at 60 weeks.1 The study results (Abstract #1694) are among the 38 abstracts across multiple rheumatic diseases being presented by AbbVie at the American College of Rheumatology (ACR) Convergence 2021, taking place virtually Nov. 3-9. "Many people living with rheumatoid arthritis continue to experience debilitating joint pain and decreased physical functioning despite being on therapy," said Thomas Hudson, M.D., senior vice president, research and development, chief scientific officer, AbbVie. "These data underscore the potential of RINVOQ to be an important treatment option to help people who face the daily challenges of rheumatoid arthritis." Of patients treated with RINVOQ who lost CDAI remission, 58% rem
Eli Lilly's oral JAK inhibitor Olumiant (Baritinib): 9.3 years of treatment, with long-term good safety!

November 19, 2021

OLUMIANT® (baricitinib) maintained a consistent safety profile in a long-term, integrated safety analysis of patients with rheumatoid arthritis (RA) who received OLUMIANT for 14,744 patient years of exposure, in line with previously published findings. Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) will present these results, along with real-world safety results from 3,445 patients with RA in Japan, at ACR Convergence 2021, the American College of Rheumatology's virtual annual meeting taking place November 3-9, 2021. Detailed and additional results from the long-term, integrated safety study for OLUMIANT were recently published in the Annals of the Rheumatic Diseases. "Rheumatoid arthritis is a chronic inflammatory disease that requires long-term treatment to manage symptoms, including joint pain, swelling and tenderness, and if left uncontrolled, can be associated with significant morbidity complications," said Professor Peter C. Taylor, M.D., Ph.D., Professor of Musculoskeletal Sciences at the University of Oxford, and lead author of this analysis. "As one of the longest safety trials for a JAK inhibitor in this disease, these data can help healthcare providers and people living with rheumatoid arthritis in better understanding OLUMIANT when considering treatment options that can be used for prolonged periods of time." OLUMIANT RA Safety Profile Remains Consistent Up to 9.3 Years A pooled analysis across nine randomized studies and one long-term extension study evaluated the safety of OLUMIANT 4-mg and OLUMIANT 2-mg over time in 3,770 patients with RA, who were exposed to treatment for a total of 14,744 patient years of exposure. Participants had a median exposure of 4.6 years and

Company Video

Cabozantinib Intermediate manufacturer / supplier